BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-101684362 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-101684362\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07524855-11220@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:JNJ-101684362: Phase 1 readout est. (NCT07524855)
DESCRIPTION:JNJ-101684362\, phase 1\, Breast Cancer.\nStudy: A Study of JNJ
 -101684362 (HLD-0117) in Patients With Metastatic Breast Cancer\nEstimated
  primary completion: 30 April 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/jnj-101684362#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07524855
URL:https://assetmemo.bio/drug/jnj-101684362#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
